A Phase II Study of CRT Combined With QL1706 in ESCC Patients

NCT05490719 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: QL1706

Sponsor

Tianjin Medical University Cancer Institute and Hospital